BRAF V600E mutation, which constitutively activates MEK phosphorylation and MAPK/ERK signaling pathway, is the most prevalent genetic alteration in follicular-derived thyroid cancer, particularly in PTC (6, 7). The gene discussed is BRAF; the disease is thyroid cancer.